Pharma

Effective July 2027, the rule requires PBMs to disclose rebates and other payments from drug makers, plus payments from pharmacies.

Our in-brief roundup of notable healthcare and life sciences stories from the last two weeks.

Research links higher launch prices with ongoing access challenges, highlighting coverage restrictions and affordability concerns for patients.

The pharma trade group claims CMS exceeded its authority with the Medicare Part B pricing model.

New Commerce Department guidance outlines narrow exemptions to 100% drug import tariffs, covering specialty therapies from 19 countries.

New pharmaceutical rules aim to expand medicine access, strengthen supply security, and reshape incentives for EU innovation.

CMS finalized a mandatory Medicare Part B payment model using pricing benchmarks to test lower drug costs while maintaining care quality.

FDA commissioner nominee Heidi Overton defended vaccine safety while declining to take firm positions on mifepristone reviews.